
John C. Lieske
Consultant, Division of Nephrology & Hypertension, Department of Internal Medicine · Mayo Clinic
Credentials: · · ·
History
Research
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
New England Journal of Medicine · 2019 · 496 citations
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine · 2021 · 427 citations
The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging
Journal of the American Society of Nephrology · 2017 · 352 citations

91 papers
- DM
50 papers

36 papers · 29 as a fellow

27 papers
- FT
22 papers

20 papers

17 papers

15 papers
Grants
- 2022–2031
An Individualized Medicine Approach to Urinary Stone Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3M · Mayo Clinic Rochester
- 2025–2030
Next Generation KUH Researchers (GENERATOR)
National Institute of Diabetes and Digestive and Kidney Diseases · U2C
Contact PI · $737.5K · Mayo Clinic Rochester
- 2022–2026
Renal Macrophages in the Pathogenesis of Human Urinary Stones and Randall's Plaque Formation in Mice
National Institute of Diabetes and Digestive and Kidney Diseases · P20
Contact PI · $1.2M · Mayo Clinic Rochester
- 1975–2025
Kidney Disease Research Training Program
National Institute of Diabetes and Digestive and Kidney Diseases · T32
Contact PI · $2.3M · Mayo Clinic Rochester
Clinical trials
- 2016–2028
- 2014–2019
Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Principal investigator · Completed · Phase 1, Phase 2
Mayo Clinic
- 2014–2015
Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study
Principal investigator · Completed · Phase 1
Mayo Clinic
- 2013–2015




